Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline characteristics of patients started on MVC treatment.

From: Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice

Characteristics

Group A1

n = 25

Group B2

n = 7

All patients

n = 32

Gender (f/m)

6/19

2/5

8/24

Median age at start MVC (years)

47

48

47

Median CD4+ T count at baseline

364

235

306.5

Median VL at baseline

829

< 50 copies/ml

280

Median number of previous drug combinations*

9

10

9

Median duration of previous antiretroviral therapy (years) *

10.2

8.5

10.1

Percentage with CCS of OBT ≥ 2

20/25

5/7

25/32

 

(80%)

(71%)

(78%)

Median CCS of OBT

2.5

2.0

2.5

  1. *Salvage drugs included darunavir, raltegravir, etravirine, enfuvirtide, and tipranavir (DRV, RAL, ETR, ENF and TPV). CCS = cumulative sensitivity score, 1HIV-RNA detectable at screening, 2HIV-RNA not detectable at screening.
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us